£7.8M
The Cambridge-based synthetic gene provider raised the capital from Mercia Ventures to expand operations and develop its DNA synthesis platform.
CB
Camena Bioscience
Camena Bioscience develops enzyme-based DNA synthesis technology for the life sciences sector.
Cambridge, UK
£7.8MTotal raised
Camena Bioscience provides synthetic genes to the pharmaceutical and biotechnology sectors through its proprietary enzyme-based platform. The firm supplies accurate DNA sequences to support disease research and drug discovery programmes.
Categories
Founders
SH
Steve Harvey
CEO
DS
Derek Stemple
CSO
Investors
